Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intas Pharma

AstraZeneca AZ

AZ gets EMA green light for severe asthma drug Fasenra

The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero

- PMLiVE

Health coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

- PMLiVE

Teva cuts 25% of workforce, with Israel taking a heavy toll

But share prices increase by almost 14%

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

- PMLiVE

Teva sheds R&D chief after new CEO takes the helm

Kåre Schultz begins remoulding the Israeli pharma firm

- PMLiVE

MSD to create strong UK discovery centre in London

The pharma group aims to start operations by 2020

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

- PMLiVE

Ex-GSK head Witty to head group overseeing UK fast-track scheme

Medicines selected for the AAP could be made available much earlier

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

Teva faces early rival to longer-acting Copaxone in US

US regulator approves Mylan’s MS drug

Teva’s Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role

- PMLiVE

Teva offloads women’s health unit in quickfire deals

The Israeli pharma group is also set to sell its oncology and pain business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links